PET and cancer screening

Annals of Nuclear Medicine

Volumn 19, Issue 3, 2005, Pages 167-177

  Yasuda, Seiei ^a   Ide, Michiru ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIMEDIC Imaging Center at Lake Yamanaka   (Japan)

Author keywords

Cancer screening; FDG PET; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER; CANCER SCREENING; CANCER STAGING; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG TUMOR LEVEL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCIDENTAL FINDING; JAPAN; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 21044441074     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984601     Document Type: Review

References (55)

1. Yasuda S, Ide M, Takagi S, Shohtsu A. Cancer screening with whole-body FDG PET. KAKU IGAKU (Jpn J Nucl Med) 1996; 33; 1065-1071.
2. 18F-fluorodeoxyglucose positron-emission tomography. Lancet 1997; 350: 1819.
3. Oottamasathien S, Crawford ED. Should routine screening for prostate-specific antigen be recommended? Arch Int Med 2003; 163: 661-662.
4. Hoffman RM. An argument against routine prostate cancer screening. Arch Int Med 2003; 163: 663-664.
5. Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol 2004; 172: 1822-1824.
6. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20: 911-920.
7. Pignone M. Faecal occult-blood screening in Burgundy. Lancet 2004; 364: 741-742.
8. Rimer BK, Briss PA, Zeller PK, Chan ECY, Woolf SH. Informed decision making: what is its role in cancer screening? Cancer 2004; 101 (5 Suppl): 1214-1228.
9. Cuzick J. Colorectal cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer screening, New York; Marcel Dekker, Inc., 1999: 219-265.
10. Moss SM. Breast cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer screening. New York; Marcel Dekker, Inc., 1999: 143-193.
11. Morimoto T, Sata M, Yamaguchi T, Kondo H, Sagara Y, Kuwamura Y, et al. Effectiveness of mammographic screening for breast cancer in women aged over 50 years in Japan. Jpn J Cancer Res 1997; 88: 778-784.
12. Miller AB. Cervix cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer screening, New York; Marcel Dekker, Inc., 1999: 195-217.
13. Falk PM, Gupta NC, Thorson AG, Frick MP, Boman BM, Christensen MA, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994; 37: 153-156.
14. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755-760.
15. 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000; 7: 85-87.
16. Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T, et al. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002; 16: 409-416.
17. 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44: 1784-1788.
18. Japanese Society for Cancer of the Colon and Rectum. Multi-institutional registry of large bowel cancer in Japan. Vol. 22, Tokyo, 2002.
19. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001; 42: 989-992.
20. Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S, et al. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 1996; 39: 449-456.
21. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 3495-3502.
22. Chang JC, Hilsenbeck SG. Prognostic and predictive markers. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Disease of the breast, Philadelphia, PA; Lippincott Williams & Wilkins, 2004: 675-696.
23. Yasuda S, Kubota M, Tajima T, Tajima T, Umemura S, Fujii H, et al. A small breast cancer detected by PET. Jpn J Clin Oncol 1999; 29: 387-389.
24. Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K, et al. Fluorine-18 2-deoxy-2-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedure. Eur J Nucl Med 2001; 28: 351-358.
25. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 2001; 36: 250-260.
26. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075-1084.
27. Mountain CF. International staging system for lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung cancer, Philadelphia, PA; Lippincott Williams & Wilkins, 2000: 591-601.
28. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer. Semin Nucl Med 2002; 32: 272-275.
29. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: 1016-1020.
30. Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, et al. Small adenocarcinoma of the lung. Cancer 1995; 75: 2844-2852.
31. Pastorino U, Bellomi M, Landoni C, Fiori ED, Arnaldi P, Picchio M, et al. Early lung-cancer screening detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003; 362: 593-597.
32. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)-usefulness and limitation in "clinical reality"-. Ann Nucl Med 2003; 17: 261-279.
33. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36: 771-777.
34. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger H, Reske SN. 2-[fluorine-18]-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-344.
35. 18F-fluorodeoxyglucose: diagnostic limitation. World J Surg 2000; 24: 1121-1129.
36. Kalady MF, Clary BM, Clark LA, Gottfried M, Rohren EM, Coleman RE, et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002; 9: 799-806.
37. Klöppel G. Pathology of nonendocrine pancreatic tumors. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The pancreas, biology, pathology, and disease, New York; Raven Press, 1993: 871-897.
38. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-1791.
39. Koyama K, Okamura T, Kawabe J, Nakata B, Hirakawa K, Ochi H, et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001; 15: 217-224.
40. Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148-156.
41. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001; 130: 941-946.
42. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by F-18- fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003; 88: 4100-4114.
43. Zhuang H, Kumar R, Mandel S, Alavi A. Investigation of thyroid, head, and neck cancers with PET. Radiol Clin N Am 2004; 42: 1101-1111.
44. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin N Am 2004; 42: 1083-1100.
45. Frenchel S, Grab D, Nuessle K, Kotzerke J, Rieber A, Kreienberg R, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223: 780-788.
46. Yasuda S, Ide M, Fujii H, Nakahara T, Mochizuki Y, Takahashi W, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer 2000; 83: 1607-1611.
47. Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 1998; 207: 775-778.
48. Horiuchi M, Yasuda S, Shohtsu A, Ide M. Four cases of Warthin's tumor of the parotid gland detected with FDG PET. Ann Nucl Med 1998; 12: 47-50.
49. 18F-FDG PET/CT. J Nucl Med 2004; 45: 1816-1821.
50. Yasuda S, Fujii H, Takahashi W, Takagi S, Ide M, Shohtsu A. Lactating breast exhibiting high F-18 FDG uptake. Clin Nucl Med 1998; 23: 767-768.
51. Yasuda S, Ide M, Takagi S, Shohtsu A. Intrauterine accumulation of F-18 FDG during menstruation. Clin Nucl Med 1997; 22: 793-794.
52. Fujii H, Ide M, Yasuda S, Takahashi W, Shohtsu A, Kubo A. Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Ann Nucl Med 1999; 13: 55-59.
53. Nakahara T, Fujii H, Ide M, Nishiumi M, Takahashi W, Yasuda S, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001; 74: 821-824.
54. Saito H. Screening for colorectal cancer. Dis Colon Rectum 2000; 43 (Suppl): S78-S84.
55. Nieminen P, Kotaniemi L, Hakama M, Tarkkanen J, Martikainen J, Toivonen T, et al. A randomised public-health trial on automation-assisted screening for cervical cancer in Finland: performance with 470,000 invitations. Int J Cancer 2005; 115: 307-311.